Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas

Journal of Pathology

Volumn 188, Issue 1, 1999, Pages 51-55

  De Krijger, Ronald R ^a,b   Van Der Harst, Erwin ^a   Van Der Ham, Frieda ^a   Stijnen, Theo ^a   Dinjens, Winand N M ^a   Koper, Jan W ^a   Bruining, Hajo A ^a   Lamberts, Steven W J ^a   Bosman, Fred T ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Bcl 2; C erbB 2; Immunohistochemistry; Oncogene; p53; Phaeochromocytoma; Prognosis

Indexed keywords

ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE C ERB; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADRENAL GLAND NEOPLASMS; ADULT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032892353     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199905)188:1<51::AID-PATH310>3.0.CO;2-R     Document Type: Article

References (39)

1. Ponder BAJ, Smith D. The MEN 2 syndromes and the role of the ret proto-oncogene. Adv Cancer Res 1996; 70: 179-222.
2. Neumann HPH, Lips CJM, Hsia YE, Zbar B. Von Hippel-Lindau syndrome. Brain Pathol 1995; 5: 181-193.
3. Bader JL. Neurofibromatosis and cancer. Ann NY Acad Sci 1986; 486: 57-65.
4. Schlumberger M, Gicquel C, Lumbroso J, et al. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 1992; 15: 631-642.
5. Pattarino F, Bouloux PM. The diagnosis of malignancy in pheochromocytoma. Clin Endocrinol 1996; 44: 239-241.
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
7. Chang F, Syrjånen S, Tervahauta A, Syrjånen K. Tumorigenesis associated with p53 tumor suppressor gene. Br J Cancer 1993; 68: 653-661.
8. Marx J. How p53 suppresses cell growth. Science 1993; 262: 1644-1645.
9. Harper JW, Adami GA, Wei N, Keyomarsi K, Elledge S. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
10. Martinez J, Georgoff I, Martinez J, Levine AJ. Cellular localization and cell cycle regulation by a temperature sensitive p53 protein. Genes Dev 1991; 5: 151-159.
11. Wynford-Thomas D. p53 in tumor pathology: can we trust immunocytochemistry. J Pathol 1992; 166: 329-330.
12. Battifora H. p53 immunohistochemistry: a word of caution. Hum Pathol 1994; 25: 435-437.
13. Hockenberry DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
14. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-886.
15. Reed JC, Meister L, Tanaka S, et al. Differential expression of bcl-2 proto-oncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 1991; 51: 6529-6538.
16. Wang DG, Barros D'Sa AAB, Johnston CF, Buchanan KD. Oncogene expression in carotid body tumors. Cancer 1996; 77: 2581-2587.
17. Wang DG, Johnston CF, Marley JJ, et al. Expression of the apoptosis-suppressing gene bcl-2 pheochromocytoma is associated with the expression of c-myc. J Clin Endocrinol Metab 1997; 82: 1949-1952.
18. Viale G, Roncalli M, Grimelius L, et al. Prognostic value of bcl-2 immuno-reactivity in medullary thyroid carcinoma. Hum Pathol 1995; 26: 945-950.
19. Castilla-Guerra L, Moreno AM, Fernández-Moreno MC, Utrilla JC, Fernández E, Galera-Davison H. Expression and prognostic value of c-erbB-2 oncogene product in human phaeochromocytomas. Histopathology 1997; 31: 144-149.
20. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erbB-related gene encoding a 185 000 Mt tumor antigen. Nature 1984; 312: 513-516.
21. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139.
22. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene product. Science 1987; 245: 177-182.
23. Gilbertson RJ, Pearson ADJ, Perry RH, Jaros E, Kelly PJ. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 1995; 71: 473-477.
24. Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA. Neuropeptide Y expression distinguishes malignant from benign pheochromocytomas. J Clin Oncol 1989; 7: 1720-1725.
25. Grouzmann E, Gicquel C, Plouin PF, Schlumberger M, Comoy E, Bohuon C. Neuropeptide Y and neuron-specific enolase levels in benign and malignant pheochromocytomas. Cancer 1990; 66: 1833-1835.
26. Tippett PA, McEwan AJ, Ackery DM. A re-evaluation of dopamine excretion in pheochromocytoma. Clin Endocrinol 1986; 25: 401-410.
27. Masmiquel L, Castro-Forns M, de Torres I, Garcia A, Vidal MT, Simó R. Leu-M1 immunoreactivity and phaeochromocytoma. J Clin Pathol 1997; 50: 168-170.
28. Unger P, Hoffman K, Pertsemlidis D, Thung S, Wolfe D, Keneko M. S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas. Arch Pathol Lab Med 1991; 115: 484-487.
29. Liu Q, Djuricin G, Staren ED, et al. Tumor angiogenesis in pheochromocytomas and paragangliomas. Surgery 1996; 120: 938-943.
30. Eng C, Foster KA, Healey CS, et al. Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma. Br J Cancer 1996; 74: 339-341.
31. Aguiar RCT, Dahia PLM, Sill H, Toledo SPA, Goldman JM, Cross NCP. Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas. Clin Endocrinol 1996; 45: 93-96.
32. Liu J, Voutilainen R, Kahn AI, Heikkilä P. Expression patterns of the c-myc gene in adrenocortical tumors and pheochromocytomas. J Endocrinol 1997; 152: 175-181.
33. Goto K, Ogo A, Yanase T, Haji M, Ohashi M, Nawata H. Expression of c-fos and c-myc proto-oncogenes in human adrenal pheochromocytomas. J Clin Endocrinol Melab 1990; 70: 353-357.
34. Pavelic K, Hrascan R, Kapitanovic S, et al. Molecular genetics of malignant insulinoma. Anticancer Res 1996; 16: 1707-1718.
35. Pavelic K, Hrascan R, Kapitanovic S, et al. Multiple genetic alterations in malignant metastatic insulinomas. J Pathol 1995; 177: 395-400.
36. Van der Harst E, de Krijger RR, Bruining HA, et al. Prognostic value of RET proto-oncogene point mutations in malignant and benign, sporadic pheochromocytomas. Int J Cancer 1998; 79: 537-540.
37. Van Dekken H, Bosman FT, Teijgeman R, et al. Identification of numerical chromosome aberrations in archival tumours by in situ hybridization to routine paraffin sections: evaluation of 23 phaeochromocytomas. J Pathol 1993; 171: 161-171.
38. Mulligan LM, Gardner E, Smith BA, Mathew CG, Ponder BA. Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2. Genes Chromosom Cancer 1993; 6: 166-177.
39. Vargas MP, Zhuang Z, Wang C, Vortmeyer A, Linehan WM, Merino MJ. Loss of heterozygosity on the short arm of chromosomes 1 and 3 in sporadic pheochromocytoma and extra-adrenal paraganglioma. Hum Pathol 1997; 28: 411-415.